One Health: connecting public and animal health

Solving RSV issues in kids and calves

Top level veterinary and biomedical research for animal and public health

WAGENINGEN
UNIVERSITY & RESEARCH

RSV in kids and calves

Bovine RSV (Respiratory Syncytial Virus) is one of the main causative agents in bovine respiratory tract disease (BRD) and has been studied for decades at the Wageningen Bioveterinary Research, in the Netherlands.

In our calf model, classical bovine RSV (bRSV) infections can be reproduced, which creates possibilities to study disease pathogenesis, host-pathogen interactions, and mechanisms of protection or enhancement after vaccination, infection or treatment of the disease.

The highly related human RSV is one of the main causative agents of respiratory illness in young infants worldwide. The options to prevent or treat RSV-infections are at present limited. Our model could be of great value in the development and selection of new intervention strategies.

Clinical infection in kids

In humans, RSV infection most commonly causes a cold-like illness, starting with a runny nose followed by coughing. Infection of the lower respiratory tract might result in bronchi(oli)tis and/or pneumonia accompanied with obstruction of the smaller airways and is characterized by (severe) tachypnoea, chest retractions and sometimes wheezing. Severe, life-threatening lower respiratory tract infections are mostly seen during primary infections in young kids.

Clinical infection in calves

In calves, bovine RSV infection usually starts with signs of an upper respiratory tract infection, including nasal discharge and cough. During course of infection, symptoms of the lower respiratory tract develop, characterized by (severe) dyspnoea and commonly accompanied with depression and fever. Peak of clinical disease is observed between day 7 and 9 post inoculation.

Summary

Our bovine RSV calf model is a homologous, predictive animal model, and clearly displays a clinical disease very similar to human RSV infection in children. This allows the model to be used as a non-human animal model for the better understanding of the human disease process. The model has proven to be a robust model for studying RSV pathogenesis and evaluating efficacy and safety of RSV candidate vaccines and therapeutics.



Contact

Wageningen Bioveterinary Research
Houtribweg 39, 8221 RA Lelystad
PO Box 65, 8200 AB Lelystad
The Netherlands

T +31 (0)320 238 007
E info.bvr@wur.nl
www.wur.nl/bioveterinary-research